Clinical trial
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With…
NCT00305903 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00305903 |
|---|---|
| Title | Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease |
| Official title | A Prospective, 26-Week, Open-Label, Multi-Center, Single-Arm Pilot Study to Evaluate the Safety and Tolerability of Rivastigmine Capsule With Add on Memantine HCl in Patients With Probable Alzheimer's Disease (MMSE 10-20) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Rivastigmine, memantine |
| Enrollment | 150 |
| Start date | Mar 1, 2006 |
| Completion | Aug 1, 2007 |
| First posted | Mar 22, 2006 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: